Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

McGuirk

Showing results (541-550 of 583) with videos related to

Pageof 59
Sort By:
Blood Advances|October 5, 2019
Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancyScott R Solomon, Andrew St Martin, Nirav N Shah, et al.
British Journal of Haematology|September 22, 2025
Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR studyCelalettin Ustun, Mei-Jie Zhang, Andrew Peterson, et al.
Pediatric Radiology|January 12, 2024
European Society of Pediatric Radiology survey of perioperative imaging in pediatric liver transplantation: (2) intraoperative imagingJochen Herrmann, Philippe Petit, Stéphanie Franchi-Abella, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 27, 2024
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational StudyJoshua A Hill, Michael J Martens, Jo-Anne H Young, et al.
Blood Advances|May 5, 2026
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphomaJoseph P McGuirk, Armin Ghobadi, Carlos R Bachier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2024
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumMichael D Jain, Jay Y Spiegel, Loretta J Nastoupil, et al.
Transplantation and Cellular Therapy|November 25, 2022
Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation SurvivorsSanghee Hong, Jing Zhao, Shu Wang, et al.
The New England Journal of Medicine|December 10, 2021
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell LymphomaFrederick L Locke, David B Miklos, Caron A Jacobson, et al.
Blood Advances|April 6, 2026
Antigen-specific T cell responses to SARS-CoV-2 vaccination after Hematopoietic Cell Transplant or CAR T cell TherapySigrun Einarsdottir, Teng Fei, Katina H Singh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2025
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell LymphomaRichard T Maziarz, Michael R Bishop, Constantine S Tam, et al.
Pageof 59

Showing results (541-550 of 583) with videos related to

Sort By:
Pageof 59
Blood Advances|October 5, 2019
Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancyScott R Solomon, Andrew St Martin, Nirav N Shah, et al.
British Journal of Haematology|September 22, 2025
Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR studyCelalettin Ustun, Mei-Jie Zhang, Andrew Peterson, et al.
Pediatric Radiology|January 12, 2024
European Society of Pediatric Radiology survey of perioperative imaging in pediatric liver transplantation: (2) intraoperative imagingJochen Herrmann, Philippe Petit, Stéphanie Franchi-Abella, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 27, 2024
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational StudyJoshua A Hill, Michael J Martens, Jo-Anne H Young, et al.
Blood Advances|May 5, 2026
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphomaJoseph P McGuirk, Armin Ghobadi, Carlos R Bachier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2024
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumMichael D Jain, Jay Y Spiegel, Loretta J Nastoupil, et al.
Transplantation and Cellular Therapy|November 25, 2022
Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation SurvivorsSanghee Hong, Jing Zhao, Shu Wang, et al.
The New England Journal of Medicine|December 10, 2021
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell LymphomaFrederick L Locke, David B Miklos, Caron A Jacobson, et al.
Blood Advances|April 6, 2026
Antigen-specific T cell responses to SARS-CoV-2 vaccination after Hematopoietic Cell Transplant or CAR T cell TherapySigrun Einarsdottir, Teng Fei, Katina H Singh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2025
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell LymphomaRichard T Maziarz, Michael R Bishop, Constantine S Tam, et al.
Pageof 59